Meeting
2016 ASCO Annual Meeting
Pharmacogenetics of treatment response in patients with high-risk neuroblastoma, a Children’s Oncology Group Study.
Authors
Navin R. Pinto
University of Chicago Hospital, Chicago, IL
Navin R. Pinto , Mary J Emond , Charles Spiekerman , Arlene Naranjo , Karen W Makar , Julie R. Park , Jeannine S. McCune
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT00567567
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10560)
DOI
10.1200/JCO.2016.34.15_suppl.10560
Abstract #
10560
Poster Bd #
251
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.
First Author: Steven G. DuBois
Poster
2017 ASCO Annual Meeting
Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).
First Author: Wayne Lee Furman
Poster
2023 ASCO Annual Meeting
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.
First Author: Theodore Willis Laetsch
Poster
2022 ASCO Annual Meeting
Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.
First Author: Kelly C. Goldsmith